Your browser is no longer supported. Please, upgrade your browser.
Settings
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E159.83 EPS (ttm)1.04 Insider Own0.30% Shs Outstand253.25M Perf Week3.08%
Market Cap42.01B Forward P/E36.62 EPS next Y4.53 Insider Trans-51.78% Shs Float251.29M Perf Month-0.93%
Income263.20M PEG2.51 EPS next Q0.62 Inst Own98.20% Short Float1.52% Perf Quarter14.33%
Sales2.49B P/S16.88 EPS this Y327.00% Inst Trans0.45% Short Ratio2.17 Perf Half Y8.25%
Book/sh8.06 P/B20.58 EPS next Y48.67% ROA8.10% Target Price192.24 Perf Year93.51%
Cash/sh8.25 P/C20.11 EPS next 5Y63.77% ROE15.10% 52W Range84.39 - 174.96 Perf YTD10.70%
Dividend- P/FCF56.36 EPS past 5Y47.60% ROI8.80% 52W High-5.18% Beta1.61
Dividend %- Quick Ratio3.10 Sales past 5Y10.30% Gross Margin89.00% 52W Low96.59% ATR5.47
Employees2300 Current Ratio3.30 Sales Q/Q42.10% Oper. Margin5.00% RSI (14)59.91 Volatility3.26% 3.69%
OptionableYes Debt/Eq0.30 EPS Q/Q191.70% Profit Margin10.60% Rel Volume0.89 Prev Close157.59
ShortableYes LT Debt/Eq0.29 EarningsJan 31 AMC Payout0.00% Avg Volume1.76M Price165.90
Recom1.80 SMA203.32% SMA506.50% SMA20013.48% Volume1,572,954 Change5.27%
Feb-13-18Reiterated JMP Securities Mkt Outperform $200 → $211
Feb-01-18Reiterated Barclays Overweight $180 → $200
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Oct-18-17Reiterated RBC Capital Mkts Outperform $175 → $181
Sep-29-17Initiated BTIG Research Buy $200
Sep-15-17Initiated RBC Capital Mkts Outperform $175
Jul-19-17Upgrade Raymond James Mkt Perform → Outperform
Jul-19-17Upgrade Janney Neutral → Buy
Jul-19-17Upgrade Barclays Equal Weight → Overweight $115 → $180
Jul-19-17Reiterated Stifel Buy $154 → $182
Jul-18-17Reiterated Stifel Buy $130 → $154
Jul-11-17Initiated Jefferies Buy
Jun-23-17Upgrade Needham Hold → Buy $155
Jun-02-17Upgrade Oppenheimer Perform → Outperform
Mar-31-17Upgrade Maxim Group Hold → Buy $143
Mar-17-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Mar-09-17Initiated UBS Buy $106
Mar-01-17Initiated Citigroup Buy $105
Jan-26-17Reiterated Stifel Buy $108 → $100
Dec-15-16Initiated Oppenheimer Perform
Feb-22-18 04:38PM  Vertex Pharma Could Launch A Cystic Fibrosis Treatment By 2019 Investor's Business Daily
11:25AM  Landmark Vertex cystic fibrosis drug could hit market by late 2019: analyst American City Business Journals
Feb-21-18 04:01PM  Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis Business Wire
08:07AM  The Zacks Analyst Blog Highlights: Amgen, TOTAL, Marriott, PG&E and Vertex Zacks
Feb-19-18 08:53AM  3 High-Growth Stocks That Could Soar Motley Fool
Feb-16-18 08:15PM  Vertex Pharmaceuticals Scores an Important Win Motley Fool
11:13AM  3 Stocks That Could Put Amazon's Future Returns to Shame Motley Fool
Feb-14-18 02:25PM  Vertex says non-opioid pain drug hits mark in study American City Business Journals
08:30AM  Vertex Announces Treatment with the NaV1.8 Inhibitor VX-150 Showed Significant Relief of Acute Pain in Phase 2 Study Business Wire
08:00AM  3 High-Growth Stocks That Are Just Getting Started Motley Fool
Feb-13-18 07:05PM  Is Now a Good Time to Buy Vertex Pharmaceuticals? Motley Fool
04:09PM  Why Payers Won't Balk At $292,000 Price Tag For Vertex's New Drug Investor's Business Daily
10:35AM  Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval Zacks
09:40AM  Stocks Off To A Weak Start; Amazon Slams Another Industry Investor's Business Daily
Feb-12-18 07:10PM  Vertex scores FDA approval for new cystic fibrosis drug American City Business Journals
06:52PM  Vertex Pharmaceuticals Incorporated (VRTX) Climbs After the FDA Okayed Its CF Medicine SmarterAnalyst
05:59PM  U.S. FDA approves Vertex cystic fibrosis combination treatment Reuters
04:50PM  FDA Approves SYMDEKOTM (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene Business Wire
03:27PM  Is AbbVie or Vertex Pharmaceuticals the Better Buy Now? Motley Fool
Feb-08-18 01:35PM  Why Crispr Therapeutics AG Stock Bolted Higher in January Motley Fool
07:31AM  The Zacks Analyst Blog Highlights: Wells Fargo, Caterpillar, Schlumberger, Vertex and Republic Services Zacks
Feb-07-18 04:17PM  Top Stock Reports for Wells Fargo, Caterpillar & Schlumberger Zacks
Feb-06-18 05:45PM  These Biotechs Could Spring Back After Market Correction: Analyst Investor's Business Daily
Feb-05-18 10:40AM  Bristol Myers earnings power shares in the green among a sea of red Yahoo Finance Video -6.68%
09:56AM  Vertex Pharma, Atlassian, This Apple Supplier Lead Six Stocks That Just Undercut Buy Points Investor's Business Daily
09:46AM  The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex Zacks
Feb-03-18 10:47AM  3 Top Orphan-Drug Stocks to Buy Now Motley Fool
Feb-02-18 07:40AM  Blog Exposure - BeiGene Commenced Dosing in Global Phase-3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with ESCC ACCESSWIRE
Feb-01-18 04:17PM  Vertex Pharmaceuticals Picks Between "Sirloin Steak and Filet Mignon" Motley Fool
09:57AM  Vertex (VRTX) Q4 Earnings Beat on Strong CF Products Sales Zacks
07:30AM  What Vertex Pharmaceuticals Just Said About Its Future Motley Fool
12:05AM  Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis Business Wire
Jan-31-18 07:36PM  Cystic fibrosis treatment moves to final stage of testing, possibly boosting patient options CNBC
06:55PM  Vertex Pharma shares rally as results top Street view MarketWatch
04:48PM  Vertex tops Street 4Q forecasts Associated Press
04:32PM  Vertex picks cystic fibrosis triple combos for Phase III trials Reuters
04:20PM  Vertex unveils promising data on new cystic fibrosis drugs as sales top $2B American City Business Journals
04:19PM  Vertex Beats Views, Closes In On Cystic Fibrosis Treatments Investor's Business Daily
04:16PM  Vertex Pharmaceuticals announces $500M stock buyback CNBC Videos
04:14PM  Vertex Picks 'Impressive' Cystic Fibrosis Drugs To Aim For A Multibillion-Dollar Market Forbes
04:05PM  Vertex Reports Full-Year and Fourth-Quarter 2017 Financial Results Business Wire
04:01PM  Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis Business Wire
04:01PM  Vertex picks cystic fibrosis triple combinations for Phase III trials Reuters
01:35PM  Earnings Preview For Vertex Pharmaceuticals Benzinga
10:00AM  Vertex Pharmaceuticals Incorporated to Host Earnings Call ACCESSWIRE
06:12AM  Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this February Zacks
Jan-30-18 06:06PM  Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX Zacks
07:20AM  Corbus Pharma gets $25M grant, FDA nod for cystic fibrosis drug trial American City Business Journals
Jan-29-18 04:44PM  Weekly CFO Sells Highlight GuruFocus.com
10:25AM  Vertex (VRTX) to Report Q4 Earnings: What's in the Cards? Zacks
Jan-27-18 12:01AM  [$$] Biotech Ready to Bust Out Barrons.com
Jan-25-18 11:55AM  Analysts Take Action on Healthcare Stocks GuruFocus.com
11:12AM  Vertex (VRTX) Stock Up 70% in a Year's Time: Here's Why Zacks
Jan-23-18 12:57PM  Here's What's Driving Crispr Therapeutics AG Higher Today Motley Fool
Jan-22-18 04:05PM  Tech, Oil Stocks Up; Will GE Hit $10? Time To Buy These 4 Dow Jones Stocks? Investor's Business Daily
Jan-19-18 04:39PM  Which Biotech Stocks Could Surprise To The Upside On Earnings? Investor's Business Daily
10:36AM  Weekly CFO Sells Highlight GuruFocus.com
Jan-18-18 01:55PM  3 Biotech Stocks Start Healthy in 18: Will the Rally Last? InvestorPlace
12:45PM  Amgen Gets FDA Nod to Add ENDEAVOR Data on Kyprolis Label Zacks
09:25AM  3 Top-Ranked Drug Stocks That Are Broker Favorites InvestorPlace
07:02AM  3 Top-Ranked Drug Stocks that are Broker Favorites Zacks
Jan-17-18 06:15PM  Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $15.6 million of Shares GuruFocus.com
09:01AM  Vertex Pharmaceuticals to Target 90% of Cystic Fibrosis Patients Market Realist
08:23AM  BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day Zacks
07:31AM  Vertex Pharmaceuticals Has Robust Late-Stage Research Pipeline Market Realist
Jan-16-18 03:11PM  3 Biotech Stocks Start Healthy in '18: Will the Rally Last? Zacks
10:45AM  Can Vertex Pharmaceuticals Report Solid 2017 Net Profit Margins? Market Realist
09:15AM  Why Vertex Pharmaceuticals Raised Its 2017 Revenue Guidance Market Realist
07:40AM  Analyst Recommendations for Vertex Pharmaceuticals in January Market Realist
Jan-12-18 03:18PM  Why Concert Pharmaceuticals, Inc. Is Singing the Blues Today Motley Fool
09:16AM  The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex Zacks
Jan-11-18 09:46AM  Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU Zacks
Jan-10-18 05:40PM  A Look at Ioniss 3Q17 Revenue Stream Market Realist
05:20PM  How Did Bioverativ Perform in 3Q17? Market Realist
03:49PM  Analysts Recommendations for Bioverativ in January 2018 Market Realist
04:00AM  Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation Business Wire
Jan-09-18 04:43PM  What Should We Expect From Vertex Pharmaceuticals Incorporateds (NASDAQ:VRTX) Earnings Over The Next Few Years? Simply Wall St.
10:23AM  Hows Incytes Valuation in January 2018? Market Realist
06:09AM  10 Things to Expect From Vertex Pharmaceuticals in 2018 Motley Fool
Jan-08-18 03:42PM  Amgen's (AMGN) Xgeva Gets FDA Approval for Multiple Myeloma Zacks
11:55AM  Vertex Pharma's Earnings Preview Benzinga
Jan-06-18 10:34AM  3 Big Biotech Stocks to Buy in January Motley Fool
Jan-05-18 01:48PM  Why CRISPR Therapeutics AG Stock Is Rising Today Motley Fool
Jan-04-18 07:13PM  The 3 Best-Performing Healthcare Stocks in the S&P 500 in 2017 Motley Fool
07:01PM  Cramer: 2017 Was a Year of Resurrection and Revival TheStreet.com
10:47AM  Here's What Pushed Crispr Therapeutics AG Up 23.6% in December Motley Fool
Jan-03-18 04:01PM  Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth-Quarter and Full-Year 2017 Financial Results Business Wire
07:11AM  Will These 2 Large-Cap Biotechs Be on Investor Radar in '18? Zacks
Jan-02-18 04:11PM  Why These 2 Biotechs Could Outperform Amid 'Hyper-Competition' Investor's Business Daily
01:10PM  Analyst names Vertex and Alexion 'top picks for 2018' American City Business Journals
08:13AM  These 4 S&P 500 Stocks Doubled in 2017 Motley Fool
Dec-29-17 01:16PM  A Market Cynic's Biotech Year In Review Forbes
Dec-27-17 05:37PM  Stocks trading at a discount according to Wall Street's a... CNBC Videos
Dec-26-17 01:16PM  Vertex Pharmaceuticals, Inc. Value Analysis (NASDAQ:VRTX) : December 26, 2017 Capital Cube
09:15AM  Is It Time To Sell Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Based Off Its PE Ratio? Simply Wall St.
Dec-22-17 11:45AM  Q&A: Vertex Chief Talks About Company's 'Transformational Year' Investor's Business Daily
10:52AM  10 Top S&P 500 Stocks in 2017 InvestorPlace
07:19AM  Vertex Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VRTX-US : December 22, 2017 Capital Cube
Dec-21-17 06:04AM  3 Great Stocks for Your IRA Motley Fool
Dec-19-17 06:00AM  Biotech Stocks Set to Rebound 7% by January Investopedia
Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; CRISPR Therapeutics AG; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Silva Paul MSVP & Corp ControllerFeb 20Sale158.493,437544,73019,525Feb 21 06:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 13Sale151.834,044614,00151,657Feb 15 04:23 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 12Sale150.826,403965,67169,999Feb 14 05:53 PM
LEIDEN JEFFREY MCEO & PresidentFeb 12Sale150.8323,9053,605,547190,658Feb 14 06:06 PM
Chodakewitz JeffreyEVP GMDA, CMOFeb 12Sale150.825,122772,49369,663Feb 14 06:15 PM
Sachdev AmitEVP, CROFeb 12Sale150.8417,7962,684,41146,662Feb 14 06:23 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 12Sale152.826,8241,042,83355,701Feb 14 06:16 PM
Parini MichaelEVP, CL&AOFeb 05Option Exercise86.522,330201,59227,823Feb 07 05:56 PM
Chodakewitz JeffreyEVP GMDA, CMOFeb 05Option Exercise109.143,594392,24956,118Feb 07 06:16 PM
Sachdev AmitEVP, CROFeb 05Option Exercise81.274,520367,32743,683Feb 07 06:26 PM
Silva Paul MSVP & Corp ControllerFeb 05Option Exercise80.862,098169,64718,732Feb 07 05:37 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 05Option Exercise93.238,500792,41350,452Feb 07 05:46 PM
Parini MichaelEVP, CL&AOFeb 05Sale163.082,330379,97625,493Feb 07 05:56 PM
Chodakewitz JeffreyEVP GMDA, CMOFeb 05Sale161.463,594580,30452,524Feb 07 06:16 PM
Sachdev AmitEVP, CROFeb 05Sale163.014,520736,80039,163Feb 07 06:26 PM
Silva Paul MSVP & Corp ControllerFeb 05Sale163.082,098342,14216,634Feb 07 05:37 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 05Sale163.088,5001,386,18041,952Feb 07 05:46 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 02Option Exercise91.052,156196,30444,108Feb 05 05:11 PM
Silva Paul MSVP & Corp ControllerFeb 02Option Exercise91.051,289117,36317,923Feb 05 05:39 PM
Chodakewitz JeffreyEVP GMDA, CMOFeb 02Option Exercise91.051,796163,52654,320Feb 05 05:43 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 02Option Exercise91.051,796163,52651,557Feb 05 05:47 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 02Sale169.422,156365,27041,952Feb 05 05:11 PM
Silva Paul MSVP & Corp ControllerFeb 02Sale169.421,289218,38216,634Feb 05 05:39 PM
Chodakewitz JeffreyEVP GMDA, CMOFeb 02Sale166.111,796298,32952,524Feb 05 05:43 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 02Sale166.111,796298,33049,761Feb 05 05:47 PM
Silva Paul MSVP & Corp ControllerFeb 01Option Exercise96.878,594832,50125,228Feb 05 05:39 PM
Parini MichaelEVP, CL&AOFeb 01Sale174.113,450600,68025,493Feb 05 05:35 PM
Silva Paul MSVP & Corp ControllerFeb 01Sale174.118,5941,496,30116,634Feb 05 05:39 PM
Chodakewitz JeffreyEVP GMDA, CMOFeb 01Sale167.441,900318,13652,524Feb 05 05:43 PM
Sachdev AmitEVP, CROJan 29Option Exercise91.0515,0851,373,48954,248Jan 30 05:10 PM
Sachdev AmitEVP, CROJan 29Sale170.0015,0852,564,45039,163Jan 30 05:10 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 24Option Exercise88.708,969795,52250,921Jan 26 04:46 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 24Sale169.008,9691,515,76141,952Jan 26 04:46 PM
Sachdev AmitEVP, CROJan 23Option Exercise86.525,824503,89244,987Jan 25 06:33 PM
Silva Paul MSVP & Corp ControllerJan 23Option Exercise90.623,008272,57219,642Jan 24 05:33 PM
MCGLYNN MARGARET GDirectorJan 23Option Exercise59.5510,000595,50016,217Jan 24 05:35 PM
Sachdev AmitEVP, CROJan 23Sale165.005,824960,96039,163Jan 25 06:33 PM
Silva Paul MSVP & Corp ControllerJan 23Sale166.053,008499,47816,634Jan 24 05:33 PM
MCGLYNN MARGARET GDirectorJan 23Sale165.0010,0001,650,0006,217Jan 24 05:35 PM
Sachdev AmitEVP, CROJan 22Option Exercise83.3613,7501,146,20052,913Jan 23 04:56 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 22Option Exercise91.051,796163,52651,557Jan 24 05:29 PM
Silva Paul MSVP & Corp ControllerJan 22Option Exercise86.522,427209,98419,061Jan 24 05:33 PM
MCGLYNN MARGARET GDirectorJan 22Option Exercise59.5510,000595,50016,217Jan 24 05:35 PM
Sachdev AmitEVP, CROJan 22Sale160.0013,7502,200,00039,163Jan 23 04:56 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 22Sale160.001,796287,36049,761Jan 24 05:29 PM
Silva Paul MSVP & Corp ControllerJan 22Sale161.522,427392,00916,634Jan 24 05:33 PM
MCGLYNN MARGARET GDirectorJan 22Sale160.0010,0001,600,0006,217Jan 24 05:35 PM
Sachdev AmitEVP, CROJan 19Option Exercise79.8832,4222,589,73271,585Jan 23 04:56 PM
Sachdev AmitEVP, CROJan 19Sale158.0832,4225,125,40039,163Jan 23 04:56 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 16Option Exercise96.872,125205,84944,077Jan 17 04:34 PM
Chodakewitz JeffreyEVP GMDA, CMOJan 16Option Exercise96.871,719166,52056,143Jan 17 04:38 PM
LEIDEN JEFFREY MCEO & PresidentJan 16Option Exercise46.7299,5634,651,914232,060Jan 17 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 16Sale158.282,125336,34541,952Jan 17 04:34 PM
Chodakewitz JeffreyEVP GMDA, CMOJan 16Sale157.281,719270,35854,424Jan 17 04:38 PM
SMITH IAN FEVP, COOJan 16Sale157.292,125334,23240,888Jan 17 04:40 PM
LEIDEN JEFFREY MCEO & PresidentJan 16Sale156.9999,56315,630,614132,497Jan 17 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 16Sale156.9956,2508,830,75549,761Jan 17 04:46 PM
Parini MichaelEVP, CL&AOJan 12Option Exercise90.292,125191,86631,068Jan 16 05:01 PM
Parini MichaelEVP, CL&AOJan 12Sale157.162,125333,96528,943Jan 16 05:01 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 11Option Exercise109.144,250463,84546,202Jan 12 04:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 11Sale159.004,250675,75041,952Jan 12 04:16 PM
Bhatia Sangeeta N.DirectorJan 05Option Exercise126.6810,7531,362,19014,706Jan 09 05:33 PM
Bhatia Sangeeta N.DirectorJan 05Sale156.0010,7531,677,4683,953Jan 09 05:33 PM
Chodakewitz JeffreyEVP GMDA, CMOJan 02Option Exercise73.513,438252,72757,862Jan 03 04:56 PM
Graney ThomasChief Financial OfficerJan 02Sale149.95777116,5118,789Jan 03 04:49 PM
Chodakewitz JeffreyEVP GMDA, CMOJan 02Sale151.803,438521,89554,424Jan 03 04:56 PM
Silva Paul MSVP & Corp ControllerDec 27Option Exercise77.311,28999,65317,923Dec 28 04:31 PM
Silva Paul MSVP & Corp ControllerDec 27Sale152.311,289196,32816,634Dec 28 04:31 PM
LEIDEN JEFFREY MCEO & PresidentDec 11Sale141.35125,00017,668,896132,497Dec 11 06:30 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 15Sale147.2922132,55141,952Nov 17 04:37 PM
Sachdev AmitEVP, CRONov 15Sale147.298312,22550,710Nov 17 04:41 PM
SMITH IAN FEVP, COONov 15Sale147.2971,03140,888Nov 17 04:44 PM
Silva Paul MSVP & Corp ControllerNov 15Sale147.29233,38816,634Nov 17 04:46 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 15Sale149.1230645,630106,011Nov 17 04:48 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 06Option Exercise77.314,250328,56846,202Nov 07 05:15 PM
SMITH IAN FEVP, COONov 06Option Exercise77.314,250328,56845,138Nov 07 05:26 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 06Sale148.174,250629,72341,952Nov 07 05:15 PM
SMITH IAN FEVP, COONov 06Sale150.004,250637,50040,888Nov 07 05:26 PM
Bhatia Sangeeta N.DirectorNov 03Option Exercise93.517,073661,39611,026Nov 07 05:12 PM
Parini MichaelEVP, CL&AONov 03Option Exercise86.522,330201,59231,139Nov 07 05:23 PM
SMITH IAN FEVP, COONov 03Option Exercise91.052,155196,21343,043Nov 07 05:26 PM
Chodakewitz JeffreyEVP GMDA, CMONov 03Option Exercise109.143,594392,24958,018Nov 06 05:50 PM
Bhatia Sangeeta N.DirectorNov 03Sale143.057,0731,011,7933,953Nov 07 05:12 PM
Parini MichaelEVP, CL&AONov 03Sale149.502,330348,33528,809Nov 07 05:23 PM
SMITH IAN FEVP, COONov 03Sale150.002,155323,25040,888Nov 07 05:26 PM
Chodakewitz JeffreyEVP GMDA, CMONov 03Sale144.693,594520,01654,424Nov 06 05:50 PM
Chodakewitz JeffreyEVP GMDA, CMONov 02Option Exercise91.051,796163,52656,220Nov 06 05:50 PM
Chodakewitz JeffreyEVP GMDA, CMONov 02Sale144.761,796259,98254,424Nov 06 05:50 PM
Sachdev AmitEVP, CROOct 31Sale145.0540,0005,802,08450,710Oct 31 06:12 PM
Chodakewitz JeffreyEVP GMDA, CMOOct 31Sale145.0560,0008,703,16154,424Oct 31 06:15 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerOct 31Sale144.8175,00010,860,64541,952Oct 31 06:16 PM
SMITH IAN FEVP, COOOct 31Sale145.0675,00010,879,85840,888Oct 31 06:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerOct 27Option Exercise96.872,125205,849119,077Oct 31 06:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerOct 27Sale143.976,290905,598116,952Oct 31 06:16 PM
Chodakewitz JeffreyEVP GMDA, CMOOct 16Option Exercise96.871,718166,423116,142Oct 18 05:35 PM
SMITH IAN FEVP, COOOct 16Option Exercise96.872,125205,849118,013Oct 18 05:41 PM
Chodakewitz JeffreyEVP GMDA, CMOOct 16Sale155.191,718266,610114,424Oct 18 05:35 PM
SMITH IAN FEVP, COOOct 16Sale155.612,125330,671115,888Oct 18 05:41 PM
Parini MichaelEVP, CL&AOOct 12Option Exercise90.292,125191,86630,934Oct 16 04:59 PM
Parini MichaelEVP, CL&AOOct 12Sale152.932,125324,97628,809Oct 16 04:59 PM